This post was originally published on this site Fatigue is the most commonly reported symptom by sarcoidosis patients in Denmark, Germany, and the Netherlands, according to a survey conducted by researchers from those countries. Nerve damage-related symptoms are a close second. The study, “The Burden of Sarcoidosis Symptoms from a Patient Perspective” was published in…
Conditions
Conditions
Phase 1/2 Trial of Tinostamustine Recruiting Patients with Myeloma, Other Blood Cancers
This post was originally published on this site The expansion part of a Phase 1/2 clinical trial testing tinostamustine in relapsed or refractory blood cancers has begun treating the first patient. The trial (NCT02576496), conducted by Mundipharma EDO in collaboration with Imbrium Therapeutics, is currently seeking about 111 adult patients in the U.S. and Europe with either…
Uterine Fluid Analysis May Aid in Early Diagnosis of Aggressive OC
This post was originally published on this site Proteomic analysis — the characterization of all proteins present in a cell at a given time — in liquid biopsies from the womb may facilitate the early diagnosis of women who are genetically predisposed to develop high-grade ovarian cancer (HGOC), a study says. The study, “Microvesicle Proteomic…
Robotic Prostatectomy is Popular, but Not Superior to Other Options, Study Says
This post was originally published on this site While current clinical data support no difference in the survival outcomes of prostate cancer patients after robotic surgery or radiation therapy, men tend to prefer surgery after consulting with their urologists and radiation oncologists, according to a small Australian study. Researchers found that treatment choices were primarily…
Music and Laughter Are Strong Medicine Against Dementia
This post was originally published on this site When my 67-year-old mother was diagnosed with stage 4 uterine cancer I was devastated. My mother already was disabled from depression and fibromyalgia, so being diagnosed a few months later with Alzheimer’s disease along with terminal cancer seemed like a cruel joke. Soon after I learned of…
Collaboration to Explore How Gut Bacteria Might Bolster Immunotherapy
This post was originally published on this site Seres Therapeutics and AstraZeneca have established a research collaboration to unravel the mechanisms by which the microbiome – the natural, beneficial community of microbes living in the gut — might enhance the efficacy of cancer immunotherapies. “Our new collaboration with Seres Therapeutics represents an important opportunity to…
Trials to Test Abexinostat in Heavily Treated DLBCL, Follicular Lymphoma
This post was originally published on this site Xynomic Pharma is preparing two new Phase 2 trials in China to explore the activity of its investigational HDAC inhibitor, abexinostat, as third-line therapy for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The trials were approved by an independent ethics committee and will be conducted…
ALZ-101 Vaccine Fares Well in Preclinical Study of Alzheimer’s Fish
This post was originally published on this site Alzinova‘s ALZ-101 vaccine — designed to target toxic forms of the amyloid beta protein that drive neurodegeneration in Alzheimer’s disease — was well-tolerated in non-human primates and displayed efficacy in a fish model of the disease. A clinical study in patients with early Alzheimer’s disease now is expected to…
Molecular Patterns of Breast Cancer May Predict Chance of Relapse Up to 20 Years Later
This post was originally published on this site Screening a woman’s breast cancer for certain genetic and molecular patterns may be used to predict the risk of the cancer returning (relapsing) up to 20 years later, a study reports. Looking at the molecular data of breast tumors of nearly 2,000 women, researchers identified specific tumor…
Phase 2 Clinical Trial of CRS-207, Keytruda Combo for MPM is Discontinued
This post was originally published on this site A combination of the immunotherapies Keytruda (pembrolizumab) and CRS-207 is safe, but has no evidence of clinical activity in adults with malignant pleural mesothelioma who failed prior lines of therapy, a Phase 2 study shows. Based on the findings and on additional data from CRS-207’s program, the therapy’s clinical…
FDA Puts Partial Hold on Venetoclax’s Multiple Myeloma Trials
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on venetoclax’s multiple myeloma trials after new safety concerns were raised during a review of the BELLINI Phase 3 trial (NCT02755597). This means that all ongoing clinical trials assessing AbbVie‘s venetoclax in multiple myeloma can no…
Patients with Platinum-sensitive Ovarian Cancer Live Longer on SOTIO’s Immunotherapy, Trial Shows
This post was originally published on this site Adding SOTIO’s ovarian cancer immunotherapy DCVAC/OvCa to standard second-line chemotherapy significantly extends the lives of women with advanced ovarian cancer who initially responded to their first-line chemotherapy, a Phase 2 trial shows. The combination also extended the time patients lived without signs of disease worsening compared with…